AR071280A1 - Complejo de inclusion formado por disulfiram y una ciclodextrina, util en el tratamiento de la dependencia de alcohol y cocaina , procedimiento de preparacion , composicion farmaceutica y uso de dicho complejo - Google Patents
Complejo de inclusion formado por disulfiram y una ciclodextrina, util en el tratamiento de la dependencia de alcohol y cocaina , procedimiento de preparacion , composicion farmaceutica y uso de dicho complejoInfo
- Publication number
- AR071280A1 AR071280A1 ARP080105738A ARP080105738A AR071280A1 AR 071280 A1 AR071280 A1 AR 071280A1 AR P080105738 A ARP080105738 A AR P080105738A AR P080105738 A ARP080105738 A AR P080105738A AR 071280 A1 AR071280 A1 AR 071280A1
- Authority
- AR
- Argentina
- Prior art keywords
- inclusion complex
- dsf
- complex according
- beta
- inclusion
- Prior art date
Links
- AUZONCFQVSMFAP-UHFFFAOYSA-N disulfiram Chemical compound CCN(CC)C(=S)SSC(=S)N(CC)CC AUZONCFQVSMFAP-UHFFFAOYSA-N 0.000 title abstract 14
- 229960002563 disulfiram Drugs 0.000 title abstract 7
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 4
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 title abstract 3
- 208000007848 Alcoholism Diseases 0.000 title abstract 2
- 201000007930 alcohol dependence Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000022497 Cocaine-Related disease Diseases 0.000 title 1
- 201000006145 cocaine dependence Diseases 0.000 title 1
- 206010013663 drug dependence Diseases 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 abstract 3
- 239000000126 substance Substances 0.000 abstract 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 abstract 1
- 238000005160 1H NMR spectroscopy Methods 0.000 abstract 1
- 238000002441 X-ray diffraction Methods 0.000 abstract 1
- 238000000113 differential scanning calorimetry Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C333/14—Dithiocarbamic acids; Derivatives thereof
- C07C333/30—Dithiocarbamic acids; Derivatives thereof having sulfur atoms of dithiocarbamic groups bound to other sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C333/14—Dithiocarbamic acids; Derivatives thereof
- C07C333/18—Esters of dithiocarbamic acids
- C07C333/20—Esters of dithiocarbamic acids having nitrogen atoms of dithiocarbamate groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/16—Cyclodextrin; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Addiction (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Nanotechnology (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Reivindicacion 1: Un complejo de inclusion caracterizado porque está formado por Disulfiram (DSF) y Ciclodextrina (CD) en proporciones 1:1 a 1:2 respectivamente. Reivindicacion 5: El complejo de inclusion de acuerdo a la reivindicacion 3 caracterizado porque es de formula 1 Reivindicacion 6: El complejo de inclusion de acuerdo a la reivindicacion 2 y 3 caracterizado porque en el difractograma de calorimetría diferencial de barrido el pico endotérmico esta desplazado a temperaturas mayores de 250sC. Reivindicacion 7: El complejo de inclusion de acuerdo a la reivindicacion 2 caracterizado porque los desplazamientos químicos en 1H-RMN para el DSF y la HP-beta-CD en forma de complejo 1:1 son: DSF: 1,292; 1,454; y HP-beta-CD: 1,115; 1,135. Reivindicacion 9: El complejo de inclusion de acuerdo a la reivindicacion 2 caracterizado porque los desplazamientos químicos en 13C-RMN para el complejo DSF-HP-beta-CD en proporcion 1:1 son: 14,016 (-0,009), 11,909 (+0,002), 53,087 (+0,935), 48,662 (+0,994). Reivindicacion 11: El complejo de inclusion de acuerdo a la reivindicacion 1 caracterizado porque el espectro de difraccion de rayos X para un complejo 1:1 se presenta con ausencia de picos. Reivindicacion 17: Un procedimiento para preparar un complejo de inclusion de acuerdo a la reivindicacion 1 caracterizado porque se lleva a cabo en un rotavapor con una temperatura del bano de 60°C a una velocidad de 160 rpm y con un vacío de 80 mm Hg, mediante las siguientes etapas: a) se mezcla en forma física hidroxipropil-beta-ciclodextrina y DSF; b) se disuelve dicha mezcla en alcohol absoluto; c) se evapora completamente el solvente en estufa a 45°C por 48 horas. Reivindicacion 20: Composicion farmacéutica caracterizada porque comprende un complejo de inclusion formado por DSF y CD de acuerdo a la reivindicacion 1. Reivindicacion 23: Uso de un complejo de inclusion de acuerdo a la reivindicacion 1 caracterizado porque sirve para preparar un medicamento destinado a tratar la dependencia de alcohol.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CL200703876A CL2007003876A1 (es) | 2007-12-28 | 2007-12-28 | Complejo de inclusion que esta formado por disulfiram y ciclodextrina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de la dependencia de alcohol y cocaina. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR071280A1 true AR071280A1 (es) | 2010-06-09 |
Family
ID=40261621
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080105738A AR071280A1 (es) | 2007-12-28 | 2008-12-23 | Complejo de inclusion formado por disulfiram y una ciclodextrina, util en el tratamiento de la dependencia de alcohol y cocaina , procedimiento de preparacion , composicion farmaceutica y uso de dicho complejo |
Country Status (5)
| Country | Link |
|---|---|
| KR (1) | KR101131296B1 (es) |
| AR (1) | AR071280A1 (es) |
| CL (1) | CL2007003876A1 (es) |
| ES (1) | ES2348887B2 (es) |
| WO (1) | WO2009083793A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2462235C1 (ru) * | 2011-05-10 | 2012-09-27 | Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию" | Лекарственная форма дисульфирама пролонгированного действия и способ ее получения |
| RU2592625C1 (ru) * | 2015-02-03 | 2016-07-27 | Станислав Анатольевич Кедик | Комплекс включения дисульфирама с циклодекстрином |
| KR20220010855A (ko) | 2020-07-20 | 2022-01-27 | 재단법인 제주테크노파크 | 디설피람 및 그 유도체를 이용한 지방세포의 분화억제 효과를 갖는 비만 개선 및 치료용 약학적 조성물 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1196033B (it) * | 1984-02-22 | 1988-11-10 | Chiesi Farma Spa | Composto ad attivita' antiinfiammatoria ottenuto per complessazione con beta-ciclodestrina e relative formulazioni farmaceutiche |
| HU213200B (en) * | 1993-05-12 | 1997-03-28 | Chinoin Gyogyszer Es Vegyeszet | The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production |
| KR20030041577A (ko) * | 2001-11-20 | 2003-05-27 | 디디에스텍주식회사 | 난용성 약물과 치환된 시클로덱스트린을 함유하는고체분산체 및 이를 함유하는 약제학적 조성물 |
-
2007
- 2007-12-28 CL CL200703876A patent/CL2007003876A1/es unknown
-
2008
- 2008-12-23 WO PCT/IB2008/003695 patent/WO2009083793A1/es active Application Filing
- 2008-12-23 ES ES201090045A patent/ES2348887B2/es not_active Expired - Fee Related
- 2008-12-23 AR ARP080105738A patent/AR071280A1/es unknown
- 2008-12-26 KR KR1020080134495A patent/KR101131296B1/ko not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR101131296B1 (ko) | 2012-03-30 |
| ES2348887B2 (es) | 2012-01-23 |
| ES2348887A1 (es) | 2010-12-16 |
| KR20090073025A (ko) | 2009-07-02 |
| CL2007003876A1 (es) | 2008-03-07 |
| WO2009083793A1 (es) | 2009-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ601347A (en) | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof | |
| Joshi et al. | Recent developments in enediyne chemistry | |
| PE20060649A1 (es) | Forma polimorfa ii de rapamicina y proceso de preparacion | |
| JP2023537484A (ja) | 嚢胞性線維症膜コンダクタンス制御因子モジュレーター | |
| RU2012144614A (ru) | Кристаллические формы макролида и их применение | |
| TW200728491A (en) | Organometallic composition | |
| AR071280A1 (es) | Complejo de inclusion formado por disulfiram y una ciclodextrina, util en el tratamiento de la dependencia de alcohol y cocaina , procedimiento de preparacion , composicion farmaceutica y uso de dicho complejo | |
| AR041679A1 (es) | Compuestos polimorfos de mesilato de imatinib | |
| CL2008003398A1 (es) | Compuestos derivados de bis-(sulfonilamino); procedimientos de sintesis; composiciones farmaceuticas que los comprende; proceso de preparacion de las composiciones farmaceuticas; y su uso en el tratamiento de osteoartritis, artritis reumatoide, neoplasias dolor agudo o cronica, enfermedad de alzheimer, entre otras. | |
| TW200844132A (en) | Fullerene film using fullerene derivative as raw material, fullerene polymer and their production methods | |
| RU2016106124A (ru) | Соли дасатиниба в аморфной форме | |
| JP2014529342A (ja) | ９−アミノメチルで置換されたテトラサイクリン系化合物 | |
| CN113905741A (zh) | 经口递送的β-内酰胺酶抑制剂的固体形式及其用途 | |
| PE20060996A1 (es) | Polimorfo cci-779 de forma ii y composiciones farmaceuticas | |
| Nowacka et al. | Structural studies on ladder phenylsilsesquioxane oligomers formed by polycondensation of cyclotetrasiloxanetetraols | |
| Yang et al. | Study on DNA-binding properties and cytotoxicity in L1210 of La (III) complex with PMBP-isonicotinoyl hydrazone | |
| JP2008524183A5 (es) | ||
| JP2009541344A5 (es) | ||
| Parveen et al. | Rationally Developed Organic Salts of Tolfenamic Acid and Its β‐Alanine Derivatives for Dual Purposes as an Anti‐Inflammatory Topical Gel and Anticancer Agent | |
| FR2973378A1 (fr) | Derives d'acide hydroxybisphosphonique bifonctionnels | |
| PE20231071A1 (es) | Formas cristalinas de (9r,13s)-13-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1- il)fenil]-6-oxo-1,6-dihidropirimidin-1-il}-3-(difluorometil)-9-metil-3,4,7,15- tetraazatriciclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-ona | |
| CN102250138B (zh) | 一种杂氮锗三环类化合物及其制备方法和应用 | |
| Ide et al. | Determination of the critical chain length for macromolecular crystallization using structurally flexible polyketones | |
| EP1948710B1 (fr) | Procede de preparation de polyhydroxyalkanoates, polymeres ainsi obtenus, compositions les comprenant, et leurs utilisations | |
| JP5494491B2 (ja) | フラーレン化合物からなるｎ型半導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |